Novartis Ag (NVS) Cost of Revenue (2009 - 2026)

Novartis Ag has disclosed Cost of Revenue across 18 years of filings, most recently posting $3.7 billion for Q2 2026.

• In Q2 2026, Cost of Revenue rose 11.68% year-over-year to $3.7 billion; the TTM figure through Jun 2026 stood at $17.3 billion (down 10.52% YoY), while the FY2025 annual figure was $13.7 billion, up 6.8% from the prior year.
• Cost of Revenue came in at $3.7 billion for Q2 2026 at Novartis Ag, up from $3.5 billion in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $9.5 billion in Q4 2024 to a low of $2.9 billion in Q3 2022.
• Average Cost of Revenue over 5 years is $4.5 billion, with a median of $3.4 billion recorded in 2023.
• Year-over-year, Cost of Revenue tumbled 31.08% in 2025 and climbed 11.68% in 2026.
• Over 5 years, Cost of Revenue stood at $8.5 billion in 2022, then advanced by 10.64% to $9.5 billion in 2023, then grew by 0.56% to $9.5 billion in 2024, then slumped by 31.08% to $6.5 billion in 2025, then slumped by 43.35% to $3.7 billion in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $3.7 billion in Q2 2026, $3.5 billion in Q1 2026, and $6.5 billion in Q4 2025.